Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00436696 · ClinicalTrials.gov registry record
Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions
A clinical trial of Recurrent Neuroblastoma and Localized Resectable Neuroblastoma, sponsored by Children's Oncology Group.
- Completed
- Registry status
- 9,350
- Enrollment target
- 2
- Study locations
NCT00436696 is a study of Recurrent Neuroblastoma and Localized Resectable Neuroblastoma that has completed, run by Children's Oncology Group. The registered enrollment target is 9,350 participants, above the 101-participant average among 9 other Recurrent Neuroblastoma trials with a reported enrollment target (9157% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT00436696, a study of Recurrent Neuroblastoma and Localized Resectable Neuroblastoma, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- 9,350 participants
- Enrollment target
- 2
- Study locations
Study Summary
This laboratory study is looking at genes in participants with neuroblastoma or noncancerous conditions. Identifying genes related to cancer may help in the study of cancer. It may also help doctors predict who is at risk of developing neuroblastoma.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
Study Locations (2)
Mississippi
- University of Mississippi Medical Center - Jackson
Pennsylvania
- Childrens Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,350 participants |
| Start Date | 2006-12-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00436696
The ClinicalTrials.gov registry entry for NCT00436696 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9,350 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 101-participant average among 9 other Recurrent Neuroblastoma trials with a reported enrollment target (9157% higher). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Recurrent Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which Laboratory Biomarker Analysis is the first listed.
NCT00436696 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Mississippi, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00436696 about?
NCT00436696 is a clinical study titled "Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions". This laboratory study is looking at genes in participants with neuroblastoma or noncancerous conditions. Identifying genes related to cancer may help in the study of cancer. It may also help doctors predict who is at risk of developing neuroblastoma.
What is the current status of trial NCT00436696?
This trial is currently completed. The enrollment target is 9,350 participants. The study started on 2006-12-11.
What conditions does trial NCT00436696 study?
This clinical trial studies the following conditions: Recurrent Neuroblastoma, Localized Resectable Neuroblastoma, Stage 4 Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma.
What interventions are being tested in trial NCT00436696?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT00436696?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00436696 being conducted?
This trial has 2 study locations across Mississippi, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
RECRUITING · Phase 1
-
Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma
ACTIVE NOT RECRUITING
-
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
ACTIVE NOT RECRUITING · Phase 1
-
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
ACTIVE NOT RECRUITING · Phase 2
-
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
COMPLETED · Phase 2
Explore more on PlainTrial
Recurrent Neuroblastoma
All registered trials for this condition
Localized Resectable Neuroblastoma
All registered trials for this condition
Mississippi
All trials with a study site in Mississippi
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.